Latest news with #AstraZenecaPharmaIndiaLimited
&w=3840&q=100)
Business Standard
6 hours ago
- Business
- Business Standard
AstraZeneca Pharma shares surge 12% after Q4 results; profit jumps 48%
Shares of AstraZeneca Pharma India rallied nearly 12 per cent on Monday after its net profit for the fourth quarter of the previous financial year (Q4 FY25) jumped 48 per cent to ₹58.25 crore year-on-year (Y-o-Y). The pharma major's stock rose as much as 11.87 per cent during the day to ₹8,919 per share, the biggest intraday gain since March 20 this year. The stock pared gains to trade 11.2 per cent higher at ₹8,875 apiece, compared to a 0.54 per cent decline in Nifty50 as of 10:54 AM. Shares of the company extended gains to their third day while they have fallen 21 per cent this year, compared to a 4.1 per cent advance in the benchmark Nifty50. AstraZeneca Pharma has a total market capitalisation of ₹22,195.5 crore, according to BSE data. Track LIVE Stock Market Updates Here AstraZeneca Pharma Q4 results The pharma major reported a 48 per cent rise in consolidated net profit for Q4 FY24 to ₹58.25 crore. Total revenue from operations stood at ₹480.48 crore, up 25.3 per cent Y-o-Y. The company also recorded significant growth across therapeutic areas, achieving a 32 per cent increase in full-year revenue compared to the previous year. In its oncology business, the pharma major reported revenue of ₹315.85 crore in Q4FY25, a rise of 31.62 per cent. Additionally, revenue from biopharmaceuticals (cardiovascular, renal and metabolism; respiratory and immunology; and vaccines and immune therapies) rose 1.9 per cent to ₹122.74 crore. The rare disease segment grew to Rs 2 crore in Q4FY25, up from Rs 0.17 crore in Q4FY24. AstraZeneca Pharma management commentary 'FY2024–25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent," said Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma. "This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet.' About AstraZeneca Pharma AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation. The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid–19 vaccine
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
AstraZeneca Pharma Q4 FY25 net profit jumps 48% to Rs 58.25 crore
AstraZeneca Pharma India on Friday reported a 48 per cent rise in consolidated net profit for the fourth quarter ended 31 March to Rs 58.25 crore. Total revenue from operations stood at Rs 480.48 crore, up 25.3 per cent year-on-year. The company also recorded significant growth across therapeutic areas, achieving a 32 per cent increase in full-year revenue compared to the previous year. Profit before tax (PBT) stood at Rs 84.15 crore in Q4FY25, compared to Rs 54.36 crore in the same quarter last year. 'FY2024–25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent. This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet,' said Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma India Limited. In its oncology business, the pharma major reported revenue of Rs 315.85 crore in Q4FY25, a rise of 31.62 per cent. Additionally, revenue from biopharmaceuticals (cardiovascular, renal and metabolism; respiratory and immunology; and vaccines and immune therapies) rose 1.9 per cent to Rs 122.74 crore. The rare disease segment grew to Rs 2 crore in Q4FY25, up from Rs 0.17 crore in Q4FY24. 'We are pleased to share that our company has, for the first time, crossed the Rs 1,700 crore mark ($200 million). Science is sustaining and growing the success of our company, helping us transform the future of healthcare, and the health of people, society, and the planet,' said Sanjeev Panchal, Country President and Managing Director of the company. The Bengaluru-based pharmaceutical firm announced its results post-market hours. Shares of the company were trading at Rs 7,980 apiece, up 0.78 per cent on the NSE.
Business Upturn
3 days ago
- Business
- Business Upturn
AstraZeneca Pharma receives CDSCO nod for expanded use of Fasenra in India
By Aditya Bhagchandani Published on May 30, 2025, 09:25 IST AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Benralizumab (brand name: Fasenra) in India for an additional medical indication. The newly approved indication allows Fasenra to be used as an add-on treatment for adult patients suffering from relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This rare autoimmune condition is known to cause inflammation of blood vessels, leading to organ damage. AstraZeneca confirmed the development in a regulatory filing to the stock exchanges on May 29, 2025, under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements. The company stated that while the permission paves the way for marketing Fasenra in India for the newly approved indication, it remains subject to receipt of additional statutory clearances if required. Fasenra is already approved in India for other eosinophilic conditions, and this marks an important expansion in its therapeutic scope, potentially benefiting more patients with complex immunological diseases. 'The receipt of this permission paves way for the marketing of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) in India for the specified additional indication,' the company noted in the filing. The company secretary Manasa R signed off the communication to both BSE and NSE. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
